Malaria vaccines

Journal of Clinical Immunology

Volumn 16, Issue 4, 1996, Pages 183-189

  Amador, Roberto ^a   Patarroyo, Manuel E ^a  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

Immune response; Malaria vaccine; Molecular design

Indexed keywords

MALARIA VACCINE;

ARTICLE; HUMAN; MALARIA; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; VACCINATION;

ANIMALS; ANTIBODIES, PROTOZOAN; EPITOPES; GAMBIA; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; INFANT; LATIN AMERICA; MALARIA; MALARIA VACCINES; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; SOUTH AMERICA; TANZANIA; VACCINES, SYNTHETIC;

EID: 0029995564     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01541223     Document Type: Article

References (51)

1. Amador R, Moreno A, Valero MV, Murillo LA, Mora AL, Rojas M, Rocha CL, Salcedo M, Guzmán F, Espejo F, Nuñez F, Patarroyo ME: The first field trials of the chemically synthetical malaria vaccine SPf66: safety, immunogenicity and protectivity. Vaccine 10:179-184, 1992
2. Lopez MC, Silva Y, Thomas MC, Garcia A, Faus MJ, Alonso PL, Martinez F, Del Real G, Alonso C: Characterization of SPf(66)n: A chimeric molecule used as a malaria vaccine. Vaccine 12:585-591, 1994
3. Moreno A, Patarroyo ME: Development of an asexual blood stage malaria vaccine. Blood 74:537-546, 1989
4. Herrington DA, Clyde DF, Davis JR, Baqar S, Murphy JR, Cortese JF, Bank RS, Nardin E, DiJohn D, Nussenzweig RS, et al.: Human studies with synthetic peptide sporozoite vaccine (NANP)3-TT and immunization with irradiated sporozoites. Bull WHO 68 (Suppl): 33-37, 1990
5. Kaslow DC, Isaacs SN, Quakyi IA, Gwadz RW, Moss B, Keister DB: Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant vaccinia virus. Science 252:1310-1313, 1991
6. Deloron P, Campbell GH, Brandling-Bennett D, Roberts JM, Schwanz IK, Odera JS, Lal AA, Osanga CO, de la Cruz V, McCulchan TM: Antibodies to Plasmodium falciparum ring-infected erythrocyte surface antigen and P. falciparum and P. malariae circumsporozoite proteins: Seasonal prevalence in Kenyan villages. Am J Trop Med Hygiene 41:395-399, 1989
7. Day KP, Marsh K: Naturally acquired immunity to Plasmodium falciparum. Immun Today 12:68-71, 1991
8. Marsh K, Howard RJ: Antigens induced on erythrocytes by P. falciparum: Expression of diverse and conserved determinants. Science 231:150-153, 1986
9. Moreno A, Clavijo P, Edelnian R, Davis J, Sztein M, Sinigaglia F, Nardin E: CD4+ T cell clones obtained from Plasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the Circumsporozoite protein. J Immunol 151:489-499, 1993
10. Hadley Terence J, Miller LH, Haynes J, David: Recognition of red cells by malaria parasites: the role of erythrocyte-binding proteins. Transfus Med Rev 5:108-122, 1995
11. Molano A, Segura C, Guzman F, Lozada D, Patarroyo ME: In human malaria protective antibodies are directed mainly against the Lys-Glu ion pair within the Lys-Glu-Lys motif of the synthetic vaccine SPf66. Parasite Immunol 14:111-124, 1992
12. Murphy VF, Rowan WC, Page MJ, Holder AA: Expression of hybrid malaria antigens in insect cells and their engineering for correct folding and secretion. Parasitology 100:177-183, 1994
13. Salterthwait AC, Arrhenius T, Hagopian RA, Zavala F, Nussenzweig V, Lerner RA: The conformational restriction of synthetic peptides, including a malaria peptide, for use as immunogens. Philo Trans Roy Soc London Ser B Biol Sci 323(3):72, 1989
14. Satterthwait AC, Chiang LC, Arrhenius T, Cabezas E, Zavala F, Dyson HJ, Wright PE, Lerner RA: The conformational restriction of synthetic vaccines tor malaria. Bull WHO 68 (Suppl):17-25, 1990
15. Merrifield R: Solid-phase peptide synthesis. I. The synthesis of of a tetrapeptide. J Am Chem Soc 85:2149-2154, 1963
16. Houghten R: General method for the rapid solid phase synthesis of large numbers of peptides: Specificity of antigen antibody interaction at the level of individual aminoacids. Proc Natl Acad Sci USA 82:5131-5135, 1995
17. Patarroyo ME, Amador R, Clavijo P, Moreno A, Guzmán F, Romero P, Tascón R, Franco A, Murillo LA, Ponton G, Trujillo G: A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 332: 158-161, 1988
18. Alonso PL, Teuscher T, Tanner M: SPf66: Research for development or development of research? Vaccine 12:99-101, 1994
19. WHO Malaria Action Programme: Guidelines for the evaluation of Plasmodium falciparum asexual blood-stage vaccines in populations exposed to natural infection, 1989, pp 1-34
20. Ballou WR: Clinical trials of plasmodium falciparum erythrocytic stage vaccines. Am J Trop Med Hyg 50:59-65, 1995
21. Alonso PL, Tanner M, Smith T, Hayes RJ, Schellenberg JRM, Lopez MC, Bastos de Azevedo I, Menendez C, Lyimo E, Weiss N, Kilama WL, Teuscher T: A trial of the synthetic malaria vaccine SPf66 in Tanzania: Rationale and design. Vaccine 12:181-186, 1994
22. Amador R, Moreno A, Murillo LA, Sierra O, Saavedra D, Mora AL, Rocha CL, Alvarado F, Falla JC, Orozco MA, Coronell CG, Ortega NM, Molano A, Velásquez JF, Valero MV, Franco LC, Guzmán F, Salazar LM, Espejo F, Mora E, Farfán R, Zapata N, Rosas JE, Calvo JC, Castro J, Quiñonez T, Nuñez F, Patarroyo ME: Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial. J Infect Dis 166:139-144, 1992
23. Patarroyo G, Franco LC, Amador R, Murillo LA, Rocha CL, Rojas M, Patarroyo ME: Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-14 years. Vaccine 10:175-178, 1992
24. Rocha CL, Murillo LA, Mora AL, Rojas M, Franco LC, Cote J, Valero MV, Moreno A, Amador R, Nuñez F, Coronell CG, Patarroyo ME: Determination of the immunization schedule for field trials with the sybthetic malaria vaccine SPf66. Parasite Immunol 14:95-109, 1992
25. Valero MV, Amador R, Galindo C, Figueroa J, Bello MS, Murillo LA, Mora AL, Patarroyo G, Rocha CL, Rojas M, Aponte JJ, Sarmiento LE, Lozada DM, Coronell CG, Onega NM, Rosas JE, Alonso PL, Patarroyo ME: Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet 341:705-710, 1993
26. Noya O, Gabaldon I, de Noya B, Borges R, Zerpa N, Urbáez JD, Madonna A, Garrido E, Jimenez MA, Borges RE, Garcia P, Reyes I, Prieto W, Colmenares C, Pabón R, Barraez T, de Caceres LG, Godoy N, Sifontes R: A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela. J Infect Dis 170:396-402, 1993
27. Sempértegui F, Estrella B, Moscoso J, Piedrahita C. L, Hernández D, Gaybor J, Naranjo P, Mancero O, Arias S, Bernal R, Córdova ME, Suarez J, Zicker F: Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in randomized double-blind placebo-controlled field trial in an endemic area of Ecuador. Vaccine 12:337-342, 1994
28. Valero MV, Amador R, Aponte JJ, Narvaez A, Galindo C, Silva Y, Rosas J, Guzman F, Patarroyo ME: "Evaluation of SPf66 malaria vaccine during a 22-month follow-up field trial in the Pacific coast of Colombia." 1996 Vaccine (in press)
29. Bothamley GH, Beck JS, Potts RC, Grange JM, Kardjito T, Ivanyi J: Specificity of antibodies and tuberculin response after occupational exposure to tuberculosis. J Infect Dis 166:182-186, 1992
30. Teuscher T, Schellenberg JRM, Bastos de Azevedo I, Hurt N, Smith T, Hayes RJ, Masanja H, Silva Y, Machin D, Kitua A, Kilama WL, Tanner M, Alonso PL: SPf66, a chemically synthesized subunit malaria vaccine, is safe and immunogenic in Tanzanians exposed to intense malaria transmission. Vaccine 12:328-336, 1994
31. Trape J, Rogier C: Efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children. Lancet 345:134-135, 1995 (abstr)
32. D'lessandro U, Leach A, Drakely ChJ, Bennett S, Olaleye BO, Fegan GW, Jawara M, Lanrerock P, George MO, Targett GAT, Greenwood BM: Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 146:462-467, 1995 (Abstr)
33. Ada G: Strategies for exploiting the immune system in the design of vaccines. Mol Immunol 28:225-230, 1995 (abstr)
34. Long CA, Daly TM, Kima P, Srivastava I: Immunity to erythrocytic stages of malarial parasites. Am J Trop Med Hyg 50:27-32, 1994
35. Mendis KN, Carter R: Clinical disease and pathogenesis in malaria. Parasitol Today 11:PT1 2-PTI 16, 1995 (abstr)
36. Salcedo M, Barreto L, Rojas M, Moya R, Cote J, Patarroyo ME: Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria. Clin Exp Immunol 84: 122-128, 1991
37. Murillo LA, Rocha CL, Mora AL, Kalil J, Goldemberg AK, Patarroyo ME: Molecular analysis of each HLA DR4 B-1 gene in malaria vaccines. Typing and subtyping by PCR technique and oligonucleotides. Parasite Immunol 13:201-210, 1992
38. Murillo LA, Tenjo F, Clavijo O, Orozco M, Sampaio S, Kalil J, Patarroyo ME: A specific T cell-receptor genotype preference in the immune response to a synthetic Plasmodium falciparum malaria vaccine. Parasite Immunol 14:87-94, 1992
39. Nardin EH, Nussenzweig RS: T cell responses to pre-erythrocytic stages of malaria: Role in protection and vaccine development against pre-erythrocytic stages. Annu Rev Immunol 11:687-727, 1993
40. Hollingdale MR, Aikawa M, Atkinson CT, Ballou WR, Chen GX, Li J, Meis JF, Sina B, Wright C, Zhu JD: Non-CS pre-erythrocytic protective antigens. Immunol Lett 25:71-76, 1990
41. Lalvani A, Aidoo M, Allsopp CE, Plebanski M, Whittle HC, Hill AV: An HLA-based approach to the design of a CTL-inducing vaccine against Plasmodium falciparum. Res Immunol 145:461-468, 1994
42. Good MF: Antigenic diversity and MHC genetics in sporozoite immunity. Immunol Lett 41:95-98, 1994
43. Romero P: Malaria vaccines. Curr Biol 4:432-441, 1992 (abstr)
44. Radack KL, Rouan G, Hedges J: The likelihood ratio. An improved measure for reporting and evaluating diagnostic test results. Arch Pathol Lab Med 110:689-693, 1986
45. Huang W, Nardelli B, Tam J: Lipophilic multiple antigen peptide system for peptide immunogen and synthetic vaccine. Mol Immunol 31:1191-1199, 1995 (abstr)
46. Hui GSN: Liposomes, muramyl dipeptide derivatives, and non-toxic lipid A derivatives as adjuvants for human malaria vaccines. Am J Trop Med Hyg 50:41-51, 1994
47. Kensil CR, Newman MJ, Coughlin RT, Soltysik S, Bedore D, Recchia J, Wu J, Marciani DJ: The use of Stimulon adjuvant to boost vaccine response. Vacc Res 2:273-281, 1995 (abstr)
48. WHO Division of Control of Tropical Diseases, World Bank: The potential impact of research and development on malaria control activities, 1993, pp 1-20 (abstr)
49. WHO: Tropical disease research: Progress 1975-94: Highlights 1993-94: Twelfth programme report of the UNDP/World Bank/ WHO Special Programme for Research and Training in Tropical Diseases (TDR). 1:57-76, 1995 (abstr)
50. WHO Division of Control of Tropical Diseases: Outline for WHO'S plan of work for malaria control 1993-2000, 1992, pp 1-21 (abstr)
51. Nájera JA, Liese BH, Hammer J: Malaria. New patterns and perspectives. 1-32, 1992 (World Bank)